A pilot study comparing a patient-centered symptom-reporting follow-up program to standard care in patients who have completed the acute phase of treatment for early breast cancer

被引：1
|
作者：
Melisko, M. E.
Mihalis, E.
Ernest, M.
Rugo, H. S.
Park, J. W.
Moasser, M. M.
Munster, P. N.
Esserman, L.
机构：
[1] Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps272
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS272
引用
收藏
页数：1
相关论文
共 11 条
  • [1] Patient-reported Outcomes in the telephone Follow-up of the PIVOG-Study (Patient-centered Interdisciplinary Treatment- and Care Concept for Oncological-Geriatric Patients)
    Lampe, K.
    Vordermark, D.
    Flessner, F.
    Boese, S.
    Jordan, K.
    Mueller-Werdan, U.
    Schmidt, H.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 : S192 - S192
  • [2] Personalised Follow-up Program after Acute Phase of Treatment in Oncology/Hematology Patients Towards Early Intervention, Better Care and Quality of Life Improvement: Results from Pasca Pilot Study
    Michallet, Mauricette
    Sobh, Mohamad
    Buono, Romain
    Poirey, Solene
    Pascu, Isabela
    Nicolas-Virelizier, Emmanuelle
    Assaad, Souad
    Belhabri, Amine
    Lebras, Laure
    Guillermin, Yann
    Rey, Philippe
    Gilis, Lila
    Nicolini, Franck E.
    Morisset, Stephane
    Couillet, Audrey
    Chvetzoff, Gisele
    Blay, Jean-Yves
    Fervers, Beatrice
    Michallet, Anne-Sophie
    [J]. BLOOD, 2019, 134
  • [3] Satisfaction with care and adherence to treatment when using patient reported outcomes to individualize follow-up care for women with early breast cancer - a pilot randomized controlled trial
    Riis, Cathrine L.
    Jensen, Pernille T.
    Bechmann, Troels
    Moller, Soren
    Coulter, Angela
    Steffensen, Karina D.
    [J]. ACTA ONCOLOGICA, 2020, 59 (04) : 444 - 452
  • [4] Maintenance immunotherapy in patients with metastatic breast cancer (MBC) who have a clinical benefit with chemotherapy. Long-term follow-up of a phase II study.
    Recchia, Francesco
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Five-Year Follow-Up of patients with early stage Breast cancer After a Randomized study comparing Additional Treatment with Viscum Album (L.) extract to chemotherapy Alone
    Troger, Wilfried
    Zdrale, Zdravko
    Stankovic, Nikola
    Matijasevic, Miodrag
    [J]. BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2012, 6 : 173 - 180
  • [6] Additional one-year follow-up study to evaluate safety and survival in patients who have completed neoadjuvant-adjuvant treatment with SB3 (trastuzumab biosimilar) or reference trastuzumab in HER2-positive early or locally advanced breast cancer.
    Pivot, Xavier
    Bondarenko, Igor
    Nowecki, Zbigniew
    Dvorkin, Mikhail
    Trishkina, Ekaterina
    Sarosiek, Tomasz
    Wojtukiewicz, Marek
    Shparyk, Yaroslav V.
    Moiseyenko, Vladimir
    Kim, Younsoo
    Lim, Jae Yun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] A randomized study comparing electronic patient-reported outcome (ePRO) monitoring with routine follow-up during trastuzumab deruxtecan treatment in patients with metastatic breast cancer (PRO-DUCE study)
    Kikawa, Yuichiro
    Uemura, Yukari
    Taira, Tetsuhiko
    Kitagawa, Chiyoe
    Maeda, Hideki
    Kato, Hiroaki
    Hashimoto, Naoki
    Hosoda, Mitsuchika
    Hamanaka, Yohei
    Tanabe, Yuko
    Yoshida, Tatsuya
    Tane, Kaori
    Takabatake, Daisuke
    Ishikawa, Takashi
    Iwamoto, Takayuki
    Yamaguchi, Takeshi
    Takiguchi, Daisuke
    Mukai, Hirofumi
    Taira, Naruto
    Sangai, Takafumi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Five-year follow-up of the phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in patients with HER2 positive early or locally advanced breast cancer
    Pivot, X.
    Burian, O.
    Bazan, F.
    Wojtukiewicz, M.
    Jang, H.
    Kim, S.
    Lee, J.
    Yoon, Y. C.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S428 - S428
  • [9] Bicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme
    M Wirth
    C Tyrrell
    K Delaere
    M Sánchez-Chapado
    J Ramon
    D M A Wallace
    J Hetherington
    F Pina
    C Heyns
    T Borchers
    T Morris
    J Armstrong
    [J]. Prostate Cancer and Prostatic Diseases, 2005, 8 : 194 - 200
  • [10] Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer:: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme
    Wirth, M
    Tyrrell, C
    Delaere, K
    Sánchez-Chapado, M
    Ramon, J
    Wallace, DMA
    Hetherington, J
    Pina, F
    Heyns, C
    Borchers, T
    Morris, T
    Armstrong, J
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2005, 8 (02) : 194 - 200
12